Zühlke

Zühlke Ventures AG, established in 2011, is the venture capital arm of Zühlke Technology Group AG. Based in Zurich, Switzerland, with additional offices in Porto, Portugal, it specializes in financing early-stage and growth-stage companies in healthtech and medical devices sectors. Zühlke Ventures invests primarily in Switzerland, the US, and German-speaking Europe, with a typical investment size ranging from CHF0.5 million to CHF1 million. The firm acts as both an investor and a co-entrepreneur, aiming to exit through trade sales within 6 to 10 years. Zühlke Group, founded in 1968, supports companies in implementing their vision from concept to market success, covering all phases of the business innovation process.

Eric Cheung

CEO APAC and Member of the Group Executive Committee

Patrick Griss Ph.D

Co-Founder

Martin Rutishauser

Partner and Board Member

Stephan Wehrli

Partner

13 past transactions

Limula

Seed Round in 2024
Limula develops an automated cell therapy manufacturing platform that combines bioreactor and centrifuge capabilities into a single device, supported by hardware, software, and consumables. The platform enables scalable, decentralized production of cell therapies by bringing manufacturing closer to patients and supporting multiple cell types. It automates complex processing steps within a closed, modular system, allowing biotech and pharmaceutical companies to move from open, manual methods to automated operations, improving efficiency, safety, and accessibility of personalized treatments.

Bottneuro

Convertible Note in 2022
Bottneuro is a company focused on developing innovative therapies for early to moderate-stage Alzheimer's Disease patients. Utilizing its proprietary NENI technology platform, Bottneuro creates non-invasive stimulation protocols that target neurons and glial cells in the brain. In addition to its work in Alzheimer's treatment, the company has developed a brain therapy system designed to alleviate chronic neuropathic pain. This system employs plant-based components and features a 3D printed cap that allows for continuous monitoring and targeted delivery of active substances within the body. By addressing the specific needs of patients with early to mild Alzheimer's disease, Bottneuro aims to enhance their quality of life through improved treatment options and medical care.

Indivi

Seed Round in 2022
Indivi is a Medical Device Software Manufacturer that is dedicated to finding solutions in clinical research and patient monitoring through innovative digital technologies. With novel, validated and patented Digital Biomarkers, we aim at measuring – with unprecedented sensitivity – changes in motor and cognitive functions in patients with neurological disorders. These novel biomarkers will establish a new standard for both pharmacological research and clinical practice.

Evismo

Seed Round in 2021
Evismo AG, established in 2018 and based in Zurich, Switzerland, specializes in web-based remote vital signs monitoring services. The company's primary offering is CardioFlex, an extended online ECG service designed for general practitioners, cardiologists, clinics, and hospitals. Evismo enables healthcare professionals to diagnose, treat, and prevent cardiac arrhythmias more effectively by providing real-time, patient-centered medical care through its online platform.

Flow Neuroscience

Series A in 2021
Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Koya Medical

Venture Round in 2020
Koya Medical, Inc. is a healthcare company based in Oakland, California, founded in 2018. The company specializes in developing innovative wearable therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. Koya Medical's technology offers active compression therapy that enhances mobility and personalized care, addressing limitations commonly associated with traditional compression methods. Its sensor-based closed-loop system provides patient-specific patterned compression, enabling healthcare providers to effectively manage conditions like chronic edema and chronic venous insufficiency. Through its breakthrough treatments, Koya Medical seeks to transform the standard of care for individuals affected by these debilitating conditions.

Lunaphore

Series A in 2017
Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

Swisstom

Series C in 2014
Swisstom AG, based in Landquart, Switzerland, specializes in the development and manufacturing of innovative medical devices focused on lung and heart function monitoring. Established in 2009, the company presents cutting-edge solutions, such as the Swisstom BB2, which allows for the monitoring of lung function in ICU patients undergoing mechanical ventilation, and the elisa 800VIT, which visualizes ventilation-related complications, facilitating immediate therapeutic intervention at the bedside. Swisstom's approach utilizes Electrical Impedance Tomography (EIT), a non-radiating technology that sets its devices apart by providing continuous, real-time monitoring of regional organ function at the patient’s bedside. The company's products are designed to support physicians and healthcare professionals in delivering life-saving treatments, particularly for patients suffering from acute respiratory distress syndrome. As of 2018, Swisstom operates as a subsidiary of SenTec AG.

DSwiss

Venture Round in 2014
DSwiss AG is a leading provider of secure digital services based in Zurich, Switzerland, specializing in protecting online data for individuals and businesses worldwide. Founded in 2008, the company offers a range of services, including digital vaults for personal documents and passwords, secure mailboxes for bank document delivery, and platforms for secure file sharing. Their solutions are designed to meet the highest security standards, making them a trusted choice for numerous banks, insurance companies, and security service providers. DSwiss also provides tailored IT services that encompass the entire project lifecycle, from planning to implementation and development. By prioritizing data security, DSwiss enables clients to safeguard their sensitive information against potential threats.

Distalmotion

Series A in 2013
Distalmotion, founded in Lausanne, Switzerland, is a medical device company dedicated to simplifying robotic surgery to enhance access to high-quality, minimally invasive care for patients in general surgery, gynecology, and urology. The company has developed a surgical robot named Dexter, which integrates the advantages of laparoscopy with those of robotics. Dexter offers an affordable solution by providing on-demand robotic surgery capabilities, combining cost-effectiveness with advanced surgical techniques.

Leman Micro Devices

Series A in 2013
Leman Micro Devices SA, founded in 2013 and based in Lausanne, Switzerland, specializes in innovative health monitoring technologies for mobile devices. The company is renowned for developing the V-Sensor, a groundbreaking miniature device that accurately measures five vital signs: blood pressure, blood oxygen, respiration rate, pulse rate, and body temperature. This device operates without the need for cuffs or calibration and provides results on-screen within one minute through the LMD e-Checkup app. With a focus on regulated consumer healthcare products, Leman Micro Devices aims to enhance personal health monitoring by integrating its technology into smartphones and wearables, thus enabling users to conveniently track their health metrics. The V-Sensor was launched at CES 2021, marking the company's entry into the health technology market.

Tenon Technology

Series A in 2013
Lower back pain is one of the most common types of back pain in adults and can be debilitating. There are many different diagnoses, but the sacroiliac (SI) joint is involved in more than 15% of cases. The joint connects the hip bones to the spinal column and as a consequence experiences constant strain. Inflammation of the SI joint is correspondingly painful. In chronic cases which are not well controlled by physiotherapy and painkillers, surgical fixation of the joint remains the only option. The market for SI joint fixation is large and is growing disproportionately compared to the back orthopaedic market as a whole

Swisstom

Series B in 2013
Swisstom AG, based in Landquart, Switzerland, specializes in the development and manufacturing of innovative medical devices focused on lung and heart function monitoring. Established in 2009, the company presents cutting-edge solutions, such as the Swisstom BB2, which allows for the monitoring of lung function in ICU patients undergoing mechanical ventilation, and the elisa 800VIT, which visualizes ventilation-related complications, facilitating immediate therapeutic intervention at the bedside. Swisstom's approach utilizes Electrical Impedance Tomography (EIT), a non-radiating technology that sets its devices apart by providing continuous, real-time monitoring of regional organ function at the patient’s bedside. The company's products are designed to support physicians and healthcare professionals in delivering life-saving treatments, particularly for patients suffering from acute respiratory distress syndrome. As of 2018, Swisstom operates as a subsidiary of SenTec AG.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.